[{"address1": "650 Castro Street", "address2": "Suite 450", "city": "Mountain View", "state": "CA", "zip": "94041", "country": "United States", "phone": "650 200 0412", "website": "https://www.altoneuroscience.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.", "fullTimeEmployees": 76, "companyOfficers": [{"maxAge": 1, "name": "Dr. Amit  Etkin M.D., Ph.D.", "age": 47, "title": "Founder, Chairman of the Board, CEO & President", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 995998, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nicholas C. Smith", "age": 35, "title": "CFO & Chief Business Officer", "yearBorn": 1989, "fiscalYear": 2024, "totalPay": 680467, "exercisedValue": 0, "unexercisedValue": 217377}, {"maxAge": 1, "name": "Mr. Michael C. Hanley M.B.A.", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 623006, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Dan  Segal B.Sc. (Hons), BCom, CA, MSc", "age": 62, "title": "Co-Founder & Strategic Advisor", "yearBorn": 1962, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Erin R. McQuade J.D.", "age": 49, "title": "General Counsel, Chief Administrative Officer & Corporate Secretary", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam  Savitz M.D., Ph.D.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 579569, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jessica  Powell", "age": 49, "title": "Chief Development Officer", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1754006400, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 3.07, "open": 3.05, "dayLow": 3.012, "dayHigh": 3.1, "regularMarketPreviousClose": 3.07, "regularMarketOpen": 3.05, "regularMarketDayLow": 3.012, "regularMarketDayHigh": 3.1, "payoutRatio": 0.0, "forwardPE": -1.0627178, "volume": 220948, "regularMarketVolume": 220948, "averageVolume": 252379, "averageVolume10days": 121900, "averageDailyVolume10Day": 121900, "bid": 2.88, "ask": 3.13, "bidSize": 22, "askSize": 5, "marketCap": 82569904, "fiftyTwoWeekLow": 1.6, "fiftyTwoWeekHigh": 15.04, "fiftyDayAverage": 2.6246, "twoHundredDayAverage": 3.61995, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -51746008, "profitMargins": 0.0, "floatShares": 17903611, "sharesOutstanding": 27072100, "sharesShort": 2049775, "sharesShortPriorMonth": 2793266, "sharesShortPreviousMonthDate": 1749772800, "dateShortInterest": 1752537600, "sharesPercentSharesOut": 0.0757, "heldPercentInsiders": 0.07481, "heldPercentInstitutions": 0.78624, "shortRatio": 5.76, "shortPercentOfFloat": 0.096099995, "impliedSharesOutstanding": 27072100, "bookValue": 5.138, "priceToBook": 0.5936162, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -63183000, "trailingEps": -2.3, "forwardEps": -2.87, "enterpriseToEbitda": 0.746, "52WeekChange": -0.66372657, "SandP52WeekChange": 0.20277917, "quoteType": "EQUITY", "currentPrice": 3.05, "targetHighPrice": 15.0, "targetLowPrice": 4.0, "targetMeanPrice": 10.33333, "targetMedianPrice": 10.0, "recommendationKey": "none", "numberOfAnalystOpinions": 6, "totalCash": 160754000, "totalCashPerShare": 5.938, "ebitda": -69324000, "totalDebt": 26438000, "quickRatio": 22.152, "currentRatio": 22.533, "debtToEquity": 19.007, "returnOnAssets": -0.22883, "returnOnEquity": -0.38039002, "freeCashflow": -39361376, "operatingCashflow": -52997000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ANRO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1754091819, "regularMarketTime": 1754078402, "exchange": "NYQ", "messageBoardId": "finmb_1675972978", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -0.651465, "regularMarketPrice": 3.05, "marketState": "CLOSED", "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1706884200000, "shortName": "Alto Neuroscience, Inc.", "postMarketChangePercent": 1.96721, "postMarketPrice": 3.11, "postMarketChange": 0.0599999, "regularMarketChange": -0.02, "regularMarketDayRange": "3.012 - 3.1", "fullExchangeName": "NYSE", "averageDailyVolume3Month": 252379, "fiftyTwoWeekLowChange": 1.4499999, "fiftyTwoWeekLowChangePercent": 0.90624994, "fiftyTwoWeekRange": "1.6 - 15.04", "fiftyTwoWeekHighChange": -11.99, "fiftyTwoWeekHighChangePercent": -0.7972074, "fiftyTwoWeekChangePercent": -66.37266, "earningsTimestampStart": 1755201600, "earningsTimestampEnd": 1755201600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.3, "epsForward": -2.87, "fiftyDayAverageChange": 0.42540002, "fiftyDayAverageChangePercent": 0.16208185, "twoHundredDayAverageChange": -0.5699501, "twoHundredDayAverageChangePercent": -0.15744695, "displayName": "Alto Neuroscience", "trailingPegRatio": null, "__fetch_time": "2025-08-02"}]